{
  "name" : "dacemirror.sci-hub.se_journal-article_9cb9debf61a8d76605e7e822bdaaba27_yuan2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Nucleic Acid–Based Functional Nanomaterials as Advanced Cancer Therapeutics",
    "authors" : [ "Ye Yuan", "Zi Gu", "Chi Yao", "Dan Luo", "Dayong Yang", "Y. Yuan" ],
    "emails" : [ "dayong.yang@tju.edu.cn", "dl79@cornell.edu" ],
    "sections" : [ {
      "heading" : null,
      "text" : "1900172 (1 of 16) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nreview www.small-journal.com\nNucleic Acid–Based Functional Nanomaterials as Advanced Cancer Therapeutics"
    }, {
      "heading" : "Ye Yuan, Zi Gu, Chi Yao, Dan Luo,* and Dayong Yang*",
      "text" : "Y. Yuan, Dr. C. Yao, Prof. D. Yang Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE) School of Chemical Engineering and Technology Tianjin University Tianjin 300350, P. R. China E-mail: dayong.yang@tju.edu.cn Dr. Z. Gu School of Chemical Engineering and Australian Centre for NanoMedicine University of New South Wales Sydney, NSW 2052, Australia Prof. D. Luo Department of Biological and Environmental Engineering Cornell University Ithaca, NY 14853, USA E-mail: dl79@cornell.edu Prof. D. Luo CAS Key Laboratory of Nano-Bio Interface Suzhou Institute of Nano-Tech and Nano-Bionics Chinese Academy of Sciences Suzhou 215123, P. R. China\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/smll.201900172.\nDOI: 10.1002/smll.201900172"
    }, {
      "heading" : "1. Introduction",
      "text" : "Nucleic acids including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are traditionally regarded as inheritable molecules and genetic materials in living systems. With the fast advance of nanotechnology, nucleic acids have been widely explored as generic materials and attracted considerable attention in recent decades.[1] In 1982, Seeman proposed\nNucleic acid–based functional nanomaterials (NAFN) have been widely used as emerging drug delivery nanocarriers for cancer therapeutics. Considerable works have demonstrated that NAFN can effectively load and protect therapeutic agents, and particularly enable targeting delivery to the tumor site and stimuli-responsive release. These outstanding performances are due to NAFN’s unique properties including inherent biological functions and sequence programmability as well as biocompatibility and biodegradability. In this Review, the recent progress on NAFN as advanced cancer therapeutics is highlighted. Three main cancer therapy approaches are categorized including chemo-, immuno-, and gene-therapy. Examples are presented to show how NAFN are rationally and exquisitely designed to address problems in cancer therapy. The challenges and future development of NAFN are also discussed toward future more practical biomedical applications.\nDrug Delivery Nanocarriers\nthat DNA could construct specific and precisely ordered nanostructure based on Watson–Crick base pairing, founding the basis for the field of “DNA structural nanotechnology.”[2–6] Afterward, in addition to DNA-based precise nanostructures, numerous nucleic acid–based functional nanomaterials (NAFN) have also been synthesized with various unique properties mainly including the intrinsic excellent biocompatibility, biodegradability, and programmable molecular recognition capacity.[7–13] By harnessing these properties, NAFN materials have been successfully applied to drug delivery,[14–16] tissue engineering,[17] bioimaging,[18,19] and biosensing,[20–22] showing great promises for biomedical applications.\nCancer remains one of the most devastating diseases that seriously threats human being’s health and life.[23,24] To fight against cancers, chemotherapy mediated by chemo drugs is among the most established therapies that have shown great level of efficacy.[25] In addition, gene therapy and immunotherapy have progressed fast as emerging cancer therapies toward the ultimate goal of improving therapeutic efficacy and meanwhile minimizing systemic side effects.[26–31] The therapeutic agents in gene therapy involve genes,[32–34] antisense oligonucleotides (ASOs),[35,36] or RNA interference (RNAi),[37–41] (e.g., small interference RNA (siRNA)[42,43] and microRNA (miRNA)[44,45]). In immunotherapy, human immune system could be stimulated by nucleic acid–based exogenous antigens such as unmethylated cytosine–phosphate–guanosine (CpG) containing oligodeoxynucleotides (ODNs) and thus produces cytokines to restrain the cancer cell proliferation.[46] To further improve therapeutic efficacy and safety to the host organism, the combinatorial therapies by integrating chemotherapy, immunotherapy, and gene therapy in one platform has been elaborately designed and developed with great potential to ablate cancers completely without toxicity concerns.[47]\nNotably, a carrier is crucial to achieve a desirable performance in the abovementioned therapeutic approaches, due to the inherent limitations of small molecular chemo agents and nucleic acid drugs. For example, chemo agents usually have low solubility in water and poor stability in serum, leading to sharply reduced treatment efficacy.[23] The low delivery efficiency to tumor sites, high systemic toxicity, and multidrug resistance also restrict their efficacy.[48–50] In addition, the naked nucleic acid drugs are extremely unstable in serum due to enzymatic degradation. The efficiency of endocytosis by cancer cells is also very low.[51,52] Hence, it is important to develop ideal\nSmall 2019, 1900172\n1900172 (2 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\ndelivery vectors to load chemo and nucleic acid drugs together in order to fully protect the cargos from degradation at the nontarget site and efficiently deliver them into target cancer cells.\nViral vectors are the first generation of drug delivery carriers for nucleic acid drugs with high transfection efficiency.[53,54] However, the high safety risk in terms of immunogenicity and mutagenic toxicity seriously hamper their further practical applications.[55] Nonviral vectors, such as liposomes,[56] polymers,[57] proteins,[58] and inorganic nanoparticles,[59] have been investigated as the second generation of delivery carriers, which demonstrate higher safety but lower transfection efficiency.[60] As an advanced nonviral material emerging in recent years, NAFN with inherent biological functions and sequence programmability as well as the biocompatibility and biodegradability show a bright prospect in cancer therapy.[61,62] NAFN can effectively load and protect therapeutic agents, achieve targeting delivery to a tumor site, and enhance cellular internalization efficiency as well as realize stimuli-responsive release.[62]\nIn this review, we provide a comprehensive summary of the recent progress on NAFN as advanced cancer therapeutics with highlights on the applications of NAFN in three main cancer therapy approaches (i.e., chemotherapy, gene therapy, and immunotherapy) (Figure 1). The upcoming challenges and future development of NAFN are discussed for further promoting the practical applications. It is highly expected that with better understanding the chemistry and biological interactions of NAFN, this multidisciplinary research area involving NAFN will witness a blooming growth and eventually benefit more patients."
    }, {
      "heading" : "2. Chemotherapy",
      "text" : "Chemotherapy, one of the most extensively applied cancer therapies, was introduced in clinic 60 years ago.[25] To overcome\nDan Luo obtained his B.S. from the University of Science and Technology of China in 1989 and his Ph.D. from the Ohio State University in 1997 . After his postdoctoral training in the School of Chemical Engineering at Cornell University, he joined Cornell faculty as an assistant professor in 2001 and was promoted to the position\nof full professor in 2011. His research interests focus on engineering DNA as both a generic and a genetic material for real-world applications.\nDayong Yang received his B.S. and M.S. degrees with Professor Xiaolin Xie at Huazhong University of Science and Technology in 2002 and 2005, respectively. In 2008, he received his Ph.D. degree with Professor Xingyu Jiang at the National Center for Nanoscience and Technology. He did his postdoctoral training\nat Cornell University in the USA with Professor Dan Luo and Radboud University Nijmegen in Netherlands with Professor Wilhelm Huck. In 2015, he joined the School of Chemical Engineering and Technology of Tianjin University as a full professor. The themes of his research include DNA-based materials, biofunctional polymers, cell-free synthetic biology, and biosensors.\nits disadvantages in inefficient delivery, systemic toxicity, and multi drug resistance,[23,50] NAFN have been developed to deliver anticancer drugs such as doxorubicin (DOX, or Adriamycin).[6] DOX is a broad-spectrum anticancer drug and easily inserts in the base pair of double-strand DNA (dsDNA), especially between guanine (G) and cytosine (C), and therefore, NAFN acts as an applicable DOX carrier for chemotherapy.[63] Various NAFN have been applied to cancer treatment by loading DOX as a model drug, including DNA origami,[64–69] DNA tetrahedron,[70–73] DNA dendrimers,[19,74,75] and DNA nanoflower.[76–81]"
    }, {
      "heading" : "2.1. DNA Origami",
      "text" : "DNA origami, first reported by Rothemund in 2006,[82] is a unique DNA folding nanotechnology to create arbitrary and precise shapes and patterns at the nanoscale. The long, singlestranded DNA (ssDNA) self-assembled by virtue of hundreds of short ssDNAs based on Watson–Crick base pairing.[82] Due to\nSmall 2019, 1900172\nFigure 1. An illustration of the applications of NAFN in three types of cancer therapies: chemotherapy, gene therapy, and immunotherapy.\n1900172 (3 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nthe properties of predefined dimension,[83] molecular addressability,[84] and stable structure,[85] DNA origami has attracted great attention in the field of biomedicine.\nDing and coworkers have developed a series of DNA origami as nanocarriers for drug delivery.[64,65,86,87] For example, they reported two types of DNA origami nanostructures, a tubular shape and a triangular shape, for DOX delivery (Figure 2a).[64] The origami nanostructures were loaded about twofold amount of DOX than unstructured dsDNA. The DOX accumulated in cancer cells with DNA nanocarriers and subsequently inhibited lysosomal acidification. In drug-resistant cells, DOX tended to concentrate in the most acidic regions, thus more DOX dispersed in cytoplasm and nucleus rather than gathered in lysosomes, circumventing drug resistance. Ding group further developed a series of triangle, square, and tube DNA origami as pH stimuli-responsive nanocarriers\nSmall 2019, 1900172\n1900172 (4 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nfor drug release (Figure 2b).[65] DOX was control released in response to the acidic tumor microenvironment by affecting the interaction between DOX and dsDNA. Among these nanostructures, the triangle-shaped DNA nanostructure showed optimal accumulation at the tumor sites due to the rational geometry and controlled nanosize (≈120 nm length of each side), which was favorable for efficient chemotherapy. Högberg and coworkers designed straight and twisted DNA origami nanotubes (S-Nano and T-Nano, respectively) and investigated the kinetics of drug release(Figure 2c).[66] Compared to the S-Nano, the T-Nano encapsulated 33% higher amount of DOX at the loading concentration of 96 × 10−6 m and triggered nonFickian diffusion, inducing controlled and slower drug release than that from S-Nano. Therefore, the T-Nano demonstrated a desirable chemotherapy effect at a lower drug dosage on three breast cancer cell lines (MDA-MB-231, MDA-MB-468, and MCF-7)."
    }, {
      "heading" : "2.2. DNA Tetrahedron",
      "text" : "DNA tetrahedrons were composed of four ssDNA to form four faces through hybridization with each other.[88] The synthetic process of DNA tetrahedron was facile, and multiple functional groups were easily decorated on their vertexes and edges. As an attractive DNA nanostructure, DNA tetrahedron was widely investigated for the applications of biosensors[89–91] and theranostics.[92] Due to the excellent biocompatibility, stability to resist nuclease degradation, and high efficiency in cellular uptake, DNA tetrahedron was demonstrated as a promising platform for drug delivery in recent years.[93] Ahn and coworkers employed the DNA tetrahedron as an antitumor drug delivery platform to overcome drug resistance in cancer cells (Figure 3a).[70] The DNA tetrahedron loaded DOX efficiently (26 DOX molecules per tetrahedron) by the inherent DNA-intercalation property of DOX.\nSmall 2019, 1900172\n1900172 (5 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nThe nanocarrier was delivered into cancer cells via endocytosis, which enabled DOX to escape the recognition by P-gp proteins on the cell membrane and therefore greatly enhanced the DOX accumulation in drug-resistant MCF-7 cells without efflux. Leong and coworkers developed a DNA tetrahedron for the codelivery of DOX and cetuximab antibody to breast cancer cells (Figure 3b).[72] A single DNA tetrahedron could stoichiometrically load one, two, and three antibodies at the vertex of tetrahedron via disulfide bonds. The DNA tetrahedron retained the loaded DOX in phosphate-buffered saline (PBS) or serum without obviously cargo loss due to the stability of the tetrahedron structures. The loaded antibodies specifically recognized the epidermal growth factor receptor on the surfaces of breast cancer cells. With the increased number of antibodies, cellular uptake efficiency and cancer cell suppression were improved. Chen and coworkers constructed a DNA tetrahedron nanocarrier for the delivery of ruthenium polypyridyl complexes (RuPOP) (Figure 3c).[73] The RuPOP was loaded between DNA strands of the tetrahedron, and furthermore improved the stability of the tetrahedron to avoid decomposition in lysosomal environment. Moreover, the DNA tetrahedron exhibited optimal loading efficacy than DNA tube or plasmid due to the higher surface area. The DNA tetrahedrons adhered to cell membranes, and thus enhanced cellular uptake due to the larger surface-contact area of DNA tetrahedrons with lower membrane bending energy barrier than the control group of tube-shaped DNA vector. Composed of ssDNAs with biotin functionalization, the DNA tetrahedrons were delivered into the target HepG2 cells and subsequently transferred to cell nucleus due to the small particle size (≈33.5 nm), which facilitated to pass through nucleopores. The nanocarriers were subsequently self-degraded by DNase, and the drugs were released in cell nucleus to induce enhanced apoptosis."
    }, {
      "heading" : "2.3. Nucleic Acid Dendrimer",
      "text" : "The branched nucleic acid constructions (e.g., X-shape and Y-shape) were composed of complementary single-strand DNA or RNA.[94,95] These branched monomers further self-assembled to form nucleic hydrogel or nanogel.[74,75,96] With the properties of monodispersity, excellent stability, and high cellular uptake efficiency,[97,98] nucleic acid dendrimers have attracted great attention in the field of biomedicine. Yang and coworkers rationally designed a dendritic DNA nanostructure as a theranostic platform that integrated the targeted drug delivery with the fluorescence imaging (Figure 4a).[19] DNA dendrimer was constructed by Y-shaped DNA monomers via layer-by-layer self-assembly with DOX inserting between the preprogrammed rich G–C pairs in branched monomers. The DNA dendrimer with sgc8 aptamers functionalized at the outside recognized PTK7 (a cell membrane protein) selectively, and the DNA dendrimers were delivered into PTK7-overexpressed cell lines. The DNA dendrimers were also internalized into\nSmall 2019, 1900172\n1900172 (6 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nHela cells via receptor-mediated endocytosis and localized in the lysosome in 2.5 h. The inserted DOX was rapidly released in response to an acidic environment and enzyme catalysis in the lysosome. In addition, multiple functional groups (e.g., fluorophores) were introduced into the dendrimers by the connection with branched DNA monomers for multifunction biomedical applications. Zhang and coworkers developed floxuridine-containing DNA and RNA nanogels based on Y-shaped branched DNA or RNA for effective drug delivery (Figure 4b).[74] The anticancer drug floxuridine was loaded onto DNA or RNA via solidphase synthesis and enzyme-mediated transcription, respectively. The nucleic acid strands self-assembled into the Y-shaped structure and subsequently formed a nanogel through the complementation of sticky ends. The nucleic acid dendrimers exhibited good stability in mimetic physiological conditions without an obvious degradation verified by gel electrophoresis; the dendrimers were degraded in the presence of DNase or RNase, inducing drug release after entering cancer cells. Guo and coworkers reported the paclitaxel-loaded, RNA-based micelles to improve drug solubility (Figure 4c).[75] The paclitaxel was connected to one end of the branched RNA via “click chemistry” and a lipophilic cholesterol module was attached at the opposite end. The modified branched RNA monomers self-assembled into micelles via hydrophobic interactions. Therefore, the RNA micelles significantly increased the water solubility and therapeutic effect of paclitaxel by virtue of the hydrophilic RNA. This work broadened the horizons of RNA-based nanomaterials in chemotherapy."
    }, {
      "heading" : "2.4. Rolling Circle Amplification (RCA)-Based DNA Nanosphere",
      "text" : "RCA is an efficient isothermal enzymatic reaction to produce DNA strands under the catalysis of DNA polymerase.[99] In a\ntypical RCA process, a predesigned circular ssDNA template is complementary to a shorter linear ssDNA which acts as the primer of the polymerase reaction.[100] In contrast to the polymerase chain reaction (PCR), a widely used method for DNA amplification, RCA produced long DNA chains with preprogrammed repeated periodic sequences at a constant temperature.[99,101] Functional DNA sequences of RCA products were rationally designed as DNA aptamers,[78,102] DNAzymes,[103,104] and rich G–C sequences with a hairpin construction.[76,78] These functional DNA motifs made RCA-based DNA nanospheres a promising platform for drug delivery.\nTan and coworkers developed multifunctional RCA-based DNA nanoparticles, designated as DNA nanoflowers (DNA NFs) (Figure 5a).[76] The DNA NFs self-assembled via liquid crystallization of the long DNA building blocks and contained a large amount of functional DNA sequences such as aptamers and drug loading sites. The size of DNA NFs was readily controlled in the range from ≈200 nm to ≈4 µm by a simple adjustment of the reaction time, the template sequence, and the substrate concentration. The high density of DNA and a myriad crosslink of the long ssDNA enhanced DNA NFs’ resistance to nuclease degradation in human serum, guaranteeing the biostability in clinical applications. Gu and coworkers prepared a cocoon-like, self-degradable DNA nanoclew for pH-responsive drug delivery (Figure 5b).[77] DNase was first embedded in acid-degradable, single protein–based nanocapsules, and subsequently coencapsulated in the RCA products with DOX to constitute the DNA nanoclews. In the acidic environment of endosome after cellular uptake, DNase was activated to rapidly degrade DNA nanoclews, thus inducing the acid-responsive drug release. The DNA nanoclew showed a high-efficiency therapy with the halfmaximal inhibitory concentration (IC50) of 1.2 × 10−6 m. Yang and coworkers designed magnetic DNA nanogels (M-DNA nanogels) for the targeted delivery and multistimuli-triggered\nSmall 2019, 1900172\n1900172 (7 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nrelease of DOX (Figure 5c).[105] M-DNA nanogels were consisted of magnetic Fe3O4 nanoparticles as the core and crosslinked ssDNA produced via RCA as the shell. The loaded drugs were released responsively upon temperature, pH, and nuclease. Moreover, the M-DNA nanogels were guided and accumulated at the tumor site; they penetrated the exterior cells and were delivered into the U87MG cells inside the tumor under an external magnetic field to enhance therapeutic efficacy."
    }, {
      "heading" : "3. Gene Therapy",
      "text" : "Gene therapy, delivering nucleic acid agents or genome-editing tools into diseased cells, have attracted increasing attention in the field of cancer treatment.[106–108] One of the great challenges of gene therapy has been to design a nonviral vector that fulfills the gene delivery promise of high delivery efficiency and high degree of safety. Toward that end, NAFN have been developed as nucleic acid carriers and promise to realize effective and targeted gene therapy.[98]"
    }, {
      "heading" : "3.1. DNA Polyhedrons",
      "text" : "DNA polyhedrons self-assembled by combining short oligonucleotides to form different 3D structures.[3] In contrast to traditional liposomes[109,110] and polymeric materials,[111,112] DNA polyhedrons have demonstrated to be desirable nucleic acid carriers with excellent biocompatibility, stable spatial structure, and controlled size.\nAnderson and coworkers prepared DNA tetrahedron nanoparticles for siRNA loading and targeted delivery (Figure 6a).[113] Six DNA strands self-assembled into a tetrahedron framework with overhung siRNA at the edges of tetrahedron through complementary base pairing. The DNA tetrahedron had a favored particle size (with the hydrodynamic diameter at ≈28.6 nm), which was large enough to circumvent renal filtration and small enough to facilitate cellular uptake. After in vivo injection, the DNA tetrahedrons were inclined to concentrate in the tumor and kidney with less accumulation in heart, liver, lung, and spleen. The silencing effect was observed at the tumor site of nude mice without an obvious immune response. Because of\nSmall 2019, 1900172\n1900172 (8 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\ntheir tunable particle size, various targeting modifications, and attached siRNA, the tetrahedrons showed great potential as a universal siRNA delivery platform. Sleiman and coworkers constructed DNA prisms that integrated stoichiometrically doublestranded ASOs for efficient gene silencing (Figure 6b).[114] The stable DNA scaffold halted the premature ASOs dissociation and enzymatic degradation in serum, leading to an enhanced gene knockdown in comparison to the ss- and ds-DNA controls. Based on the same principle, Sleiman group also synthesized the minimal DNA nanocages for encapsulating and delivering oligonucleotide drugs for gene therapy (Figure 6c).[115] The siRNA was encapsulated inside the DNA nanocage through complementary base pairing with the ssDNA (at the edge of the nanocage for binding siRNA), thus protecting the cargo from nuclease degradation. Notably, the ssDNA edges recognized the trigger strands (Bcl-2 and Bcl-xL mRNA) and strand displacements were induced. As a result, the siRNAs were released with a high release yield about 99%."
    }, {
      "heading" : "3.2. DNA Nanovehicles Formed by RCA",
      "text" : "As an efficient isothermal enzymatic reaction, RCA, which produced massive long ssDNA with preprogrammed periodic sequences, was also utilized for gene therapy by producing or encapsulating therapeutic agents.[116,117] Hammond and coworkers presented a sponge-like, DNA-based microsphere self-assembled via the RCA for ASOs delivery (Figure 7a).[116] The DNA microspheres were constructed by long ssDNA containing a considerable number of repeating ASO sequence produced via RCA; they subsequently shrunk to a smaller size (from ≈1.8 µm to ≈212 nm after the entire condensing process) after coated with cationic polymers (e.g., poly-l-lysine and polyethylenimine) via a layer-by-layer assembly technique. Through the in vivo biodistribution study, the condensed microsphere showed a favorable particle size for cellular uptake and avoiding renal clearance conformed. Gu and coworkers synthesized a unique DNA nanoclew (DNA NC) via RCA method for Cas9 protein and single guide RNA (sgRNA) complex delivery (Figure 7b).[117] The surface of DNA NC was coated with a cationic polymer polyethylenimine to accelerate the endosomal escape. The preprogrammed partial complementarity between the ssDNA of DNA NC and sgRNA facilitated the encapsulation of the gene editing tool and remarkably improved its efficacy. Furthermore, they demonstrated that the strong but reversible interaction of the complementarity contributed to the balance of Cas9/sgRNA loading and release, and subsequently influenced the efficacy of gene editing. This work also provided a novel strategy for the delivery of other DNA-binding proteins. Weizmann and coworkers designed DNA nanoribbons (DNRs) using a long ssDNA produced from RCA by DNA origami for intracellular gene silencing (Figure 7c).[118] The long ssDNA acted as a scaffold strand and three shorter ssDNAs or a longer ssDNA acted as staple strands to produce two kinds of DNRs (DNR-T and DNR-S). Owing to the relatively high aspect ratio and the rigid structure, DNRs were efficiently internalized into H460 cells and escaped from endosomes without involving proton pumps inducing enhanced siRNA delivery. This work integrated DNA origami with RCA, and provided an ingenious\nmethod for designing siRNA delivery system based on DNA nanotechnology."
    }, {
      "heading" : "3.3. Three-Way Junction Motif of Packaging RNA (3WJ-pRNA)",
      "text" : "The fast advance of DNA-based material has enabled the design, synthesis, and application of RNA-based material with various nanostructures, precisely controlled size, and shape.[119] RNA-based materials were fabricated based on both the Watson–Crick and the noncanonical base pairing (such as guanine with adenine or uracil).[120] Due to their flexible structure,[119,121] numerous loops and motifs,[122,123] and a higher thermal stability[124] than DNA-based materials, RNA-based materials showed enormous potential as alternative gene therapeutic agents.[125–127]\nGuo and coworkers developed a versatile 3WJ-pRNA platform for siRNA and miRNA delivery,[128–131] which demonstrated high thermostability and excellent resistance to enzymatic degradation in vivo.[132,133] They constructed selfassembled multifunctional RNA tetrahedrons by using 3WJpRNA motif as the vertexes and six linker RNA strands as the edges (Figure 8a).[130] Diverse functional groups (i.e., aptamers, ribozymes, and siRNA) were incorporated into the nanostructure at the edges of the RNA tetrahedron without sacrificing their biological functionalities. Moreover, the size of the tetrahedrons was precisely controlled by adjusting the length of involved RNA strands (from 22 to 55 bp per edge). RNA tetrahedrons with aptamers selectively bound to MDA-MB-231 cells and distributed in the tumor without obvious accumulation in normal organs (liver, lung, spleen, and kidney). Therefore, the RNA tetrahedrons hold a great potential to serve as a multifunctional nanocarrier for cancer therapy. Zhang and coworkers designed 3WJ-pRNA-based nanoparticles for treating breast cancers with tamoxifen resistance (Figure 8b).[134] The cross-talk between coactivator Mediator Subunit 1 (MED1) and HER2 that overexpressed on the cell membrane of human breast cancer cells played a crucial role in the mechanism of tamoxifen resistance.[135] The siMED1 and HER2 aptamer were linked with the end of 3WJ-pRNA for silencing MED1 expression and targeted delivery, respectively. The RNA nanoparticles silenced nearly 70% of MED1 mRNA in BT474 cells, and greatly reduced MED1 protein level in vitro. The combined treatment of tamoxifen and RNA nanoparticles almost completely inhibited the drug-resistant tumor growth; whereas, tamoxifen only weakly suppressed tumor growth in vivo. The RNA nanoparticles showed a great potential to address the tamoxifen resistant human breast cancer in clinical treatment. Guo group further decorated 3WJ-pRNA on extracellular vesicles (EVs) for improved siRNA loading and cell-targeting delivery (Figure 8c).[131] One end of 3WJ-pRNA was conjugated with cholesterol to insert into the EV membrane via hydrophobic interaction, and the other end was linked with a prostate-specific membrane antigen on the EV exterior surface for the targeted delivery. The EVs displayed an overall negative charge on the surface due to functionalized RNA, which reduced the nonspecific binding to normal cells. In addition, the novel nanocarrier also facilitated endosome escape and achieved high delivery efficiency.\nSmall 2019, 1900172\n1900172 (9 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1900172\n1900172 (10 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com"
    }, {
      "heading" : "3.4. RNA Nanoparticles Formed by Rolling Circle Transcription (RCT)",
      "text" : "Similar to RCA, RCT produced long single-strand RNA with preprogrammed circular DNA template in the presence of RNA polymerases through rolling circle amplification.[136–138] As an efficient enzymatic reaction to generate multiple as well as repetitive designed RNA sequences, RCT has also applied to the field of siRNA delivery.[139]\nHammond and coworkers designed the characteristic RNA microsponges for efficient siRNA delivery (Figure 9a).[140] The multiple and repetitive hairpin RNA strand containing an siRNA sequence was synthesized via RCT and subsequently self-assembled to sponge-like RNA microspheres. The RNA microsponges were disposed by Dicer in the RNAi pathway to generate a large amount of siRNA for gene silencing. The RNA microsponges were significantly internalized by T22 cells and induced significant gene silencing at an extremely low dosage (2.1 fmol). Acting as both carrier and cargo, the RNA microsponges effectively protected siRNA from degradation due to the crystalline form of polymeric RNA and achieved high cargo delivery with negligible cytotoxicity. Ahn and coworkers reported DNA-hybridized RNA nanoparticles as unique siRNA delivery nanocarrier (Figure 9b).[141] After the generation of reduplicative RNA hairpins via RCT, DNA–cholesterol and folate–DNA conjugates were hybridized with the RNA products via Watson–Crick base pairing. Hence, the RNA/DNA hybrids self-assembled and condensed into compact nanoparticles via hydrophobic interactions without using additional polycationic agents, which not only realized full protection of the loaded\nRNA agents from enzymatic degradation but also avoided the risk of potential cytotoxicity and immunogenicity induced by polycationic reagents. The RNA nanoparticles were internalized into folate receptor-positive SKOV3 cells. The evaluation of red fluorescent protein (RFP) fluorescence in SKOV3-RFP xenograft tumors indicated that the RFP signals decreased 80% after double-injection in 2 days, demonstrating a high efficiency of gene knockdown. Lee and coworkers developed a new RNA-based cargo for boosting RNA interference (Figure 9c).[142] The two kinds of long single RNA strands produced via RCT contained both sense and antisense of siRNA sequence. The strands sequentially hybridized to formed double-stranded region (precursor of siRNA) and single-stranded region (bubble region). These RNA strands further self-assembled into nanoparticles, and the double stranded region generated functional siRNA following the Dicer cleavage in cytoplasm. The evaluation of the subcutaneous implantation of nude mouse models of GFP-expressing Hela indicated that the GFP signal sharply reduced 90% in 4 days after the injection of RNA nanoparticles (0.8 fmol per mouse)."
    }, {
      "heading" : "4. Immunotherapy",
      "text" : "The unmethylated CpG containing ODNs can be recognized by the mammalian innate immune system through the ligation with toll-like receptors (TLRs).[143] Subsequently, stimulated by CpG, the innate immune system produces cytokines[144] (e.g., tumor necrosis factor (TNF)-α and interleukin (IL)-6) from dendritic cells, B cells, and macrophages[145] which\nSmall 2019, 1900172\n1900172 (11 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1900172\nenhances the anticancer activities of these immune cells. As such, CpG ODNs have been widely used as adjuvant in cancer immunotherapy.[146,147] However, the naked CpG ODNs have low cell internalization efficiency and easy degradation before reaching the target site.[148] To address these challenges, great efforts have been devoted to design NAFN for CpG ODNs delivery.\nTakakura and coworkers developed a series of DNA dendrimer nanostructures for CpG delivery.[149–151] They prepared dendrimer-like DNA by ligating Y-shaped branched DNA monomers containing CpG sequences via layer-bylayer. (Figure 10a).[152] The dendrimer-like DNA demonstrated 50-fold and 3–5-fold higher production of TNF-α and IL-6 by RAW264.7 macrophage-like cells than that of pure branched DNA monomers, respectively. It was inferred that the branched nanostructure protected CpG ODNs from rapid degradation and increased the chance of recognition by TLR, thus inducing an enhanced immunostimulatory activity. The novel design opened a new avenue of CpG ODNs delivery with safety and significant immune effect. Ding and coworkers reported a functional DNA dendrimer for efficient CpG ODNs delivery and enhanced cytokines production (Figure 10b).[153] The hairpin–loop DNA structures containing the CpG sequence were added onto the framework formed by X-shaped and Y-shaped branched DNA to enhance the resistance of the endonuclease degradation. The cell-penetrating peptide was also modified on the outermost layer of the dendrimer via linker DNA to increase CpG uptake and the endosomal accumulation. As a result, the unique CpG\nnanocarrier triggered remarkably stronger immune response than the Loop-CpG and bare DNA dendrimers. Nishikawa group designed a series of polypod-like structures (consisting of three to eight ODNs) involving the CpG sequence (Figure 10c).[154] The increasing pod number highly enhanced cellular uptake because the exposed DNA ends were recognized by TLP9 on the cell membrane, leading to a considerable amount of cytokines production.\nThe abovementioned DNA nanostructures such as DNA tetrahedron, DNA origami, and DNA nanoclew have also been explored for CpG ODNs delivery. Fan and coworkers prepared functional DNA tetrahedrons with CpG ODNs appending at the vertex (Figure 11a).[155] The DNA tetrahedrons were efficiently internalized by RAW264.7 cells and induced the high-level production of cytokines (9–18-fold higher than bare CpG ODNs). The DNA tetrahedrons were structurally rigid and intrinsically resistant to nuclease degradation in serum. Moreover, the DNA tetrahedron gradually enhanced the production of numerous cytokines with the increasing quantity of appending CpG ODNs for stronger immunostimulatory effect. Liedl and coworkers designed DNA origami nanotubes covered with CpG ODNs for triggering strong immunostimulation (Figure 11b).[156] The CpG ODNs were anchored on the surface of hollow DNA tube that was prepared by DNA origami. The novel DNA material showed no obvious toxicity and meanwhile induced intense immune responses in contrast with the control DNA components which induced undetectable level of IL-6. The stability and compactness of the DNA nanotube backbone enabled the resistance to the degradation in serum and effectively delivered large\n1900172 (12 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1900172\namount of CpG ODNs. Gu and coworkers designed the CpG ODNs and anti-PD1 codelivery system for postsurgical anticancer immunotherapy (Figure 11c).[157] The designed DNA nanococoons contained CpG sequences produced via RCA and encapsulated anti-PD1 as well as the restriction enzyme HhaI caged by triglycerol monostearate. The proteolytic enzymes that were secreted at the wound site after surgery released the triglycerol monostearate-caged HhaI, which converted DNA nanococoons into CpG ODNs and sequentially released anti-PD1. The duplex cancer immunotherapy triggered stronger immune responses than the single free CpG ODNs or anti-PD1, thus showing a significant efficacy to tumor regression among the mice with tumor excision. The novel self-degraded DNA nanococoons served as a new strategy of localized and bioresponsive release of therapeutics for cancer therapy."
    }, {
      "heading" : "5. Conclusions and Outlook",
      "text" : "In this review, we summarized recent research on NAFN for cancer therapy. The NAFN function as both vehicles and\ncargos in the three cancer therapies (chemotherapy, gene therapy, and immunotherapy). On the other hand, the development of NAFN faces challenges for true clinical translation. First, certain basic cell mechanisms such as endocytosis and endosomal escape remain largely unexplored, which restricts the understanding of cancer therapeutics.[158] Second, the degradation and human immune responses to exogenous nucleic acid seriously affect the stability of NAFN in blood circulation, thus reducing the effective concentration of therapeutic agents at tumor sites. Third, the multiple physiological barriers in human organism such as vascular barrier, reticuloendothelial system, glomerular filtration, and blood–brain barrier hinder the delivery of nanocarriers to the tumor sites.[159] In addition, the preparation methods of NAFN are usually sophisticated and costly, which makes them difficulty in scale-up production.\nAlthough NAFN is still at the nascent stage, it is highly believed that, with the fast advance in nanotechnology and biotechnology, the unique genetic nucleic acid material existing for billions of years will address the critical issues in cancer therapy and work for broader biomedical applications.\n1900172 (13 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1900172"
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was supported in part by National Natural Science Foundation of China (grant nos.: 21621004, 21575101, 21622404, 21704074, and 21778071), and China Postdoctoral Science Foundation (grant no. 2018M631735). The authors thank Jigang Lv and Chunxia Liu for discussion.\nConflict of Interest The authors declare no conflict of interest.\nKeywords cancer therapeutics, DNA nanostructures, drug delivery, nanocarriers, nanomaterials\nReceived: January 10, 2019 Revised: March 4, 2019\nPublished online:\n[1] D. Yang, M. R. Hartman, T. L. Derrien, S. Hamada, D. An, K. G. Yancey, R. Cheng, M. Ma, D. Luo, Acc. Chem. Res. 2014, 47, 1902. [2] N. C. Seeman, J. Theor. Biol. 1982, 99, 237. [3] Y. He, T. Ye, M. Su, C. Zhang, A. E. Ribbe, W. Jiang, C. Mao, Nature\n2008, 452, 198. [4] J. Zheng, J. J. Birktoft, Y. Chen, T. Wang, R. Sha, P. E. Constantinou,\nS. L. Ginell, C. Mao, N. C. Seeman, Nature 2009, 461, 74. [5] H. Yan, S. H. Park, G. Finkelstein, J. H. Reif, T. H. LaBean, Science\n2003, 301, 1882. [6] A. V. Pinheiro, H. Dongran, W. M. Shih, Y. Hao, Nat. Nanotechnol.\n2011, 6, 763. [7] D. Yang, M. J. Campolongo, T. N. Nhi Tran, R. C. Ruiz, J. S. Kahn,\nD. Luo, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2010, 2, 648. [8] S. Peng, T. L. Derrien, J. Cui, C. Xu, D. Luo, Mater. Today 2012, 15, 190. [9] Y. H. Roh, R. C. H. Ruiz, S. Peng, J. B. Lee, D. Luo, Chem. Soc. Rev. 2011, 40, 5730. [10] P. A. Guerette, S. Hoon, Y. Seow, M. Raida, A. Masic, F. T. Wong, V. H. B. Ho, K. W. Kong, M. C. Demirel, A. Pena-Francesch, Nat. Biotechnol. 2013, 31, 908.\n1900172 (14 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1900172\n[11] E. F. Khisamutdinov, D. L. Jasinski, P. Guo, ACS Nano 2014, 8, 4771. [12] C. A. Mirkin, R. L. Letsinger, R. C. Mucic, J. J. Storhoff, Nature 1996, 382, 607. [13] S. Y. Park, A. K. R. Lytton-Jean, B. Lee, S. Weigand, G. C. Schatz, C. A. Mirkin, Nature 2008, 451, 553. [14] J. Li, C. Zheng, C. Sena, C. Wu, J. Xu, C. Cui, Y. Liu, W. Hou, Y. Wang, L. Zhang, J. Am. Chem. Soc. 2015, 137, 1412. [15] J. Song, K. Im, S. Hwang, J. Hur, J. Nam, G. O. Ahn, S. Hwang, S. Kim, N. Park, Nanoscale 2015, 7, 9433. [16] S. Li, Q. Jiang, S. Liu, Y. Zhang, Y. Tian, C. Song, J. Wang, Y. Zou, G. J. Anderson, J. Y. Han, Nat. Biotechnol. 2018, 36, 258. [17] C. Li, A. Faulkner-Jones, A. R. Dun, J. Jin, P. Chen, Y. Xing, Z. Yang, Z. Li, W. Shu, D. Liu, Angew. Chem., Int. Ed. 2015, 54, 3957. [18] Q. Yuan, Y. Wu, J. Wang, D. Lu, Z. Zhao, T. Liu, X. Zhang, W. Tan, Angew. Chem. 2013, 125, 14215. [19] H. Zhang, Y. Ma, Y. Xie, Y. An, Y. Huang, Z. Zhu, C. J. Yang, Sci. Rep. 2015, 5, 10099. [20] L. Jing, L. Yi, J. Am. Chem. Soc. 2000, 122, 10466. [21] F. Li, X. Han, S. Liu, Biosens. Bioelectron. 2011, 26, 2619. [22] Y. Peng, X. Wang, Y. Xiao, L. Feng, C. Zhao, J. Ren, X. Qu, J. Am.\nChem. Soc. 2009, 131, 13813. [23] P. Dan, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit,\nR. Langer, Nat. Nanotechnol. 2007, 2, 751. [24] A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, J. Con-\ntrolled Release 2015, 200, 138. [25] R. W. Johnstone, A. A. Ruefli, S. W. Lowe, Cell 2002, 108, 153. [26] W. F. Anderson, Science 1984, 226, 401. [27] T. Friedmann, Science 1989, 244, 1275. [28] W. F. Anderson, Science 1992, 256, 808. [29] S. A. Rosenberg, Nature 2001, 411, 380. [30] S. A. Rosenberg, J. C. Yang, N. P. Restifo, Nat. Med. 2004, 10, 909. [31] J. Couzin-Frankel, Science 2013, 342, 1432. [32] L. Naldini, U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage,\nI. M. Verma, D. Trono, Science 1996, 272, 263. [33] J. Panyam, V. Labhasetwar, Adv. Drug Delivery Rev. 2003, 55, 329. [34] M. A. Mintzer, E. E. Simanek, Chem. Rev. 2009, 109, 259. [35] C. A. Stein, Y. C. Cheng, Science 1993, 261, 1004. [36] C. Rinaldi, M. J. A. Wood, Nat. Rev. Neurol. 2018, 14, 9. [37] T. R. Brummelkamp, R. Bernards, R. Agami, Cancer Cell 2002, 2,\n243. [38] V. N. Ngo, R. E. Davis, L. Lamy, X. Yu, H. Zhao, G. Lenz,\nL. T. Lam, S. Dave, L. M. Yang, J. Powell, L. M. Staudt, Nature 2006, 441, 106. [39] C. V. Pecot, G. A. Calin, R. L. Coleman, G. Lopez-Berestein, A. K. Sood, Nat. Rev. Cancer 2011, 11, 59. [40] A. Fire, S. Q. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, C. C. Mello, Nature 1998, 391, 806. [41] G. J. Hannon, Nature 2002, 418, 244. [42] J. O. McNamara, E. R. Andrechek, Y. Wang, K. D. Viles,\nR. E. Rempel, E. Gilboa, B. A. Sullenger, P. H. Giangrande, Nat. Biotechnol. 2006, 24, 1005. [43] Z. Medarova, W. Pham, C. Farrar, V. Petkova, A. Moore, Nat. Med. 2007, 13, 372. [44] A. Eulalio, E. Huntzinger, E. Izaurralde, Cell 2008, 132, 9. [45] S. Yu, Z. Lu, C. Liu, Y. Meng, Y. Ma, W. Zhao, J. Liu, J. Yu, J. Chen,\nCancer Res. 2010, 70, 6015. [46] D. M. Klinman, Nat. Rev. Immunol. 2004, 4, 249. [47] V. Tsouris, M. K. Joo, S. H. Kim, I. C. Kwon, Y. Y. Won, Biotechnol.\nAdv. 2014, 32, 1037. [48] B. A. Chabner, J. T. Roberts, Nat. Rev. Cancer 2005, 5, 65. [49] P. K. Singal, N. Iliskovic, N. Engl. J. Med. 1998, 339, 900. [50] M. M. Gottesman, Annu. Rev. Med. 2002, 53, 615. [51] H. Yin, R. L. Kanasty, A. A. Eltoukhy, A. J. Vegas, J. R. Dorkin,\nD. G. Anderson, Nat. Rev. Genet. 2014, 15, 541.\n[52] M. E. Barry, D. Pintogonzález, F. M. Orson, G. J. Mckenzie, G. R. Petry, M. A. Barry, Hum. Gene Ther. 1999, 10, 2461. [53] M. A. Kay, J. C. Glorioso, L. Naldini, Nat. Med. 2001, 7, 33. [54] R. Waehler, S. J. Russell, D. T. Curiel, Nat. Rev. Genet. 2007, 8, 573. [55] C. E. Thomas, A. Ehrhardt, M. A. Kay, Nat. Rev. Genet. 2003, 4,\n346. [56] T. M. Allen, P. R. Cullis, Adv. Drug Delivery Rev. 2013, 65, 36. [57] R. Duncan, Nat. Rev. Cancer 2006, 6, 688. [58] M. J. Hawkins, P. Soon-Shiong, N. Desai, Adv. Drug Delivery Rev.\n2008, 60, 876. [59] Y. Chen, H. Chen, J. Shi, Mol. Pharmaceutics 2014, 11, 2495. [60] D. Luo, W. M. Saltzman, Nat. Biotechnol. 2000, 18, 33. [61] M. Elsabahy, A. Nazarali, M. Foldvari, Curr. Drug Delivery 2011, 8,\n235. [62] H. Lee, A. K. R. Lytton-Jean, Y. Chen, K. T. Love, A. I. Park,\nE. D. Karagiannis, A. Sehgal, W. Querbes, C. S. Zurenko, M. Jayaraman, C. G. Peng, K. Charisse, A. Borodovsky, M. Manoharan, J. S. Donahoe, J. Truelove, M. Nahrendorf, R. Langer, D. G. Anderson, Nat. Nanotechnol. 2012, 7, 389. [63] D. Agudelo, P. Bourassa, G. Bérubé, H. A. Tajmir-Riahi, Int. J. Biol. Macromol. 2014, 66, 144. [64] Q. Jiang, C. Song, J. Nangreave, X. Liu, L. Lin, D. Qiu, Z. G. Wang, G. Zou, X. Liang, H. Yan, B. Ding, J. Am. Chem. Soc. 2012, 134, 13396. [65] Q. Zhang, Q. Jiang, N. Li, L. Dai, Q. Liu, L. Song, J. Wang, Y. Li, J. Tian, B. Ding, ACS Nano 2014, 8, 6633. [66] Y. X. Zhao, A. Shaw, X. Zeng, E. Benson, A. M. Nyström, B. Högberg, ACS Nano 2012, 6, 8684. [67] E. Tasciotti, Nat. Biotechnol. 2018, 36, 234. [68] P. Wang, M. A. Rahman, Z. Zhao, K. Weiss, C. Zhang, Z. Chen,\nS. J. Hurwitz, Z. G. Chen, M. S. Dong, Y. Ke, J. Am. Chem. Soc. 2018, 140, 2478. [69] Q. Jiang, Y. Shi, Q. Zhang, N. Li, P. Zhan, L. Song, L. Dai, J. Tian, Y. Du, Z. Cheng, Small 2015, 11, 5134. [70] K. R. Kim, D. R. Kim, T. Lee, J. Y. Yhee, B. S. Kim, I. C. Kwon, D. R. Ahn, Chem. Commun. 2013, 49, 2010. [71] Z. Xia, P. Wang, X. Liu, T. Liu, Y. Yan, J. Yan, J. Zhong, G. Sun, D. He, Biochemistry 2016, 55, 1326. [72] M. I. Setyawati, R. V. Kutty, D. T. Leong, Small 2016, 12, 5601. [73] Y. Huang, W. Huang, L. Chan, B. Zhou, T. Chen, Biomaterials 2016,\n103, 183. [74] Y. Ma, H. Liu, Q. Mou, D. Yan, X. Zhu, C. Zhang, Nanoscale 2018,\n10, 8367. [75] Y. Shu, H. Yin, M. Rajabi, H. Li, M. Vieweger, S. Guo, D. Shu,\nP. Guo, J. Controlled Release 2018, 14, 5071. [76] G. Zhu, R. Hu, Z. Zhao, Z. Chen, X. Zhang, W. Tan, J. Am. Chem.\nSoc. 2013, 135, 16438. [77] W. Sun, T. Jiang, Y. Lu, M. Reiff, R. Mo, Z. Gu, J. Am. Chem. Soc.\n2014, 136, 14722. [78] H. Zhao, X. Yuan, J. Yu, Y. Huang, C. Shao, F. Xiao, L. Lin, Y. Li,\nL. Tian, ACS Appl. Mater. Interfaces 2018, 10, 15418. [79] R. Hu, X. Zhang, Z. Zhao, G. Zhu, T. Chen, T. Fu, W. Tan, Angew.\nChem., Int. Ed. 2014, 53, 5821. [80] Y. Lv, R. Hu, G. Zhu, X. Zhang, L. Mei, Q. Liu, L. Qiu, C. Wu,\nW. Tan, Nat. Protoc. 2015, 10, 1508. [81] L. Mei, G. Zhu, L. Qiu, C. Wu, H. Chen, H. Liang, S. Cansiz, Y. Lv,\nX. Zhang, W. Tan, Nano Res. 2015, 8, 3447. [82] P. W. K. Rothemund, Nature 2006, 440, 297. [83] B. Saccà, C. M. Niemeyer, Angew. Chem., Int. Ed. 2012, 51, 58. [84] E. Stulz, G. Clever, M. Shionoya, C. Mao, Chem. Soc. Rev. 2011, 40,\n5633. [85] M. Qian, X. Wei, F. Su, L. Yan, C. Youngbull, R. Johnson,\nS. Lindsay, H. Yan, D. Meldrum, Nano Lett. 2011, 11, 1477. [86] J. Liu, L. Song, S. Liu, Q. Jiang, Q. Liu, N. Li, Z. G. Wang, B. Ding,\nNano Lett. 2018, 18, 3328.\n1900172 (15 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\nSmall 2019, 1900172\n[87] J. Liu, L. Song, S. Liu, S. Zhao, Q. Jiang, B. Ding, Angew. Chem., Int. Ed. 2018, 57, 15486. [88] R. P. Goodman, R. M. Berry, A. J. Turberfield, Chem. Commun. 2004, 12, 1372. [89] H. Pei, L. Liang, G. B. Yao, J. Li, Q. Huang, C. Fan, Angew. Chem., Int. Ed. 2012, 51, 9020. [90] Z. Ge, M. Lin, P. Wang, H. Pei, J. Yan, J. Shi, Q. Huang, D. He, C. Fan, X. Zuo, Anal. Chem. 2014, 86, 2124. [91] Y. Zhang, Z. Shuai, H. Zhou, Z. Luo, B. Liu, Y. Zhang, L. Zhang, S. Chen, J. Chao, L. Weng, Q. Fan, C. Fan, W. Huang, L. Wang, J. Am. Chem. Soc. 2018, 140, 3988. [92] H. Pei, X. Zuo, D. Zhu, Q. Huang, C. Fan, Acc. Chem. Res. 2014, 47, 550. [93] A. S. Walsh, H. Yin, C. M. Erben, M. J. Wood, A. J. Turberfield, ACS Nano 2011, 5, 5427. [94] S. H. Um, J. B. Lee, N. Park, Y. K. Sang, C. C. Umbach, L. Dan, Nat. Mater. 2006, 5, 797. [95] F. Pi, Z. Hui, L. Hui, V. Thiviyanathan, D. G. Gorenstein, A. K. Sood, P. Guo, Nanomedicine 2017, 13, 1183. [96] J. B. Lee, Y. H. Roh, S. H. Um, H. Funabashi, W. Cheng, J. J. Cha, P. Kiatwuthinon, D. A. Muller, D. Luo, Nat. Nanotechnol. 2009, 4, 430. [97] M. A. Mintzer, M. W. Grinstaff, Chem. Soc. Rev. 2011, 40, 173. [98] J. Li, C. Zheng, S. Cansiz, C. Wu, J. Xu, C. Cui, Y. Liu, W. Hou,\nY. Wang, L. Zhang, I. T. Teng, H. H. Yang, W. Tan, J. Am. Chem. Soc. 2015, 137, 1412. [99] M. M. Ali, F. Li, Z. Zhang, K. Zhang, D. K. Kang, J. A. Ankrum, X. C. Le, W. Zhao, Chem. Soc. Rev. 2014, 43, 3324. [100] J. Geng, C. Yao, X. Kou, J. Tang, D. Luo, D. Yang, Adv. Healthcare Mater. 2018, 7, 1700998. [101] W. Zhao, M. M. Ali, M. A. Brook, Y. Li, Angew. Chem., Int. Ed. 2008, 47, 6330. [102] W. Zhao, C. H. Cui, S. Bose, D. Guo, C. Shen, W. P. Wong, K. Halvorsen, O. C. Farokhzad, G. S. L. Teo, J. A. Phillips, Proc. Natl. Acad. Sci. USA 2012, 109, 19626. [103] M. M. Ali, Y. Li, Angew. Chem., Int. Ed. 2009, 48, 3512. [104] H. Dong, C. Wang, Y. Xiong, H. Lu, H. Ju, X. Zhang, Biosens. Bioel-\nectron. 2013, 41, 348. [105] C. Yao, Y. Yuan, D. Yang, ACS Appl. Bio Mater. 2018, 1, 2012. [106] R. Mulligan, Science 1993, 260, 926. [107] I. M. Verma, N. Somia, Nature 1997, 389, 239. [108] L. Naldini, Nature 2015, 526, 351. [109] K. Buyens, S. C. D. Smedt, K. Braeckmans, J. Demeester,\nL. Peeters, L. A. V. Grunsven, X. D. M. D. Jeu, R. Sawant, V. Torchilin, K. Farkasova, J. Controlled Release 2012, 158, 362. [110] C. R. Safinya, K. E. Kai, R. N. Majzoub, C. Leal, New J. Chem. 2014, 38, 5164. [111] M. E. Davis, Mol. Pharmaceutics 2009, 6, 659. [112] K. A. Whitehead, R. Langer, D. G. Anderson, Nat. Rev. Drug Dis-\ncovery 2009, 8, 129. [113] H. Lee, A. K. Lytton-Jean, Y. Chen, K. T. Love, A. I. Park,\nE. D. Karagiannis, A. Sehgal, W. Querbes, C. S. Zurenko, M. Jayaraman, C. G. Peng, K. Charisse, A. Borodovsky, M. Manoharan, J. S. Donahoe, J. Truelove, M. Nahrendorf, R. Langer, D. G. Anderson, Nat. Nanotechnol. 2012, 7, 389. [114] J. J. Fakhoury, C. K. McLaughlin, T. W. Edwardson, J. W. Conway, H. F. Sleiman, Biomacromolecules 2014, 15, 276. [115] K. E. Bujold, J. C. C. Hsu, H. F. Sleiman, J. Am. Chem. Soc. 2016, 138, 14030. [116] Y. H. Roh, J. B. Lee, K. E. Shopsowitz, E. C. Dreaden, S. W. Morton, Z. Poon, J. Hong, I. Yamin, D. K. Bonner, P. T. Hammond, ACS Nano 2014, 8, 9767. [117] W. Sun, W. Ji, J. M. Hall, Q. Hu, C. Wang, C. L. Beisel, Z. Gu, Angew. Chem., Int. Ed. 2015, 54, 12029.\n[118] G. Chen, D. Liu, C. He, T. R. Gannett, W. Lin, Y. Weizmann, J. Am. Chem. Soc. 2015, 137, 3844. [119] P. Guo, F. Haque, B. Hallahan, R. Reif, H. Li, Nucleic Acid Ther. 2012, 22, 226. [120] S. Lemieux, F. Major, Nucleic Acids Res. 2002, 30, 4250. [121] P. Guo, Nat. Nanotechnol. 2010, 5, 833. [122] Y. Ikawa, K. Tsuda, S. Matsumura, T. Inoue, Proc. Natl. Acad. Sci.\nUSA 2004, 101, 13750. [123] N. B. Leontis, A. Lescoute, E. Westhof, Curr. Opin. Struct. Biol.\n2006, 16, 279. [124] Y. Shu, F. Pi, A. Sharma, M. Rajabi, F. Haque, D. Shu, M. Leggas,\nB. M. Evers, P. Guo, Adv. Drug Delivery Rev. 2014, 66, 74. [125] T. J. Lee, J. Y. Yoo, D. Shu, H. Li, J. Zhang, J. G. Yu, A. C. Jaime-Ramirez,\nM. Acunzo, G. Romano, R. Cui, H. L. Sun, Z. Luo, M. Old, B. Kaur, P. Guo, C. M. Croce, Mol. Ther. 2017, 25, 1544. [126] C. Xu, F. Haque, D. L. Jasinski, D. W. Binzel, D. Shu, P. Guo, Cancer Lett. 2018, 414, 57. [127] A. Sharma, F. Haque, F. Pi, L. S. Shlyakhtenko, B. M. Evers, P. Guo, Nanomedicine 2016, 12, 835. [128] P. Guo, O. Coban, N. M. Snead, J. Trebley, S. Hoeprich, S. Guo, Y. Shu, Adv. Drug Delivery Rev. 2010, 62, 650. [129] A. Khaled, S. Guo, L. Feng, P. Guo, Nano Lett. 2005, 5, 1797. [130] H. Li, K. Zhang, F. Pi, S. Guo, L. Shlyakhtenko, W. Chiu, D. Shu,\nP. Guo, Adv. Mater. 2016, 28, 7501. [131] F. Pi, D. W. Binzel, T. J. Lee, Z. Li, M. Sun, P. Rychahou, H. Li,\nF. Haque, S. Wang, C. M. Croce, B. Guo, B. M. Evers, P. Guo, Nat. Nanotechnol. 2018, 13, 82. [132] D. Shu, Y. Shu, F. Haque, S. Abdelmawla, P. Guo, Nat. Nanotechnol. 2011, 6, 658. [133] H. Zhang, J. A. Endrizzi, Y. Shu, F. Haque, C. Sauter, L. S. Shlyakhtenko, Y. Lyubchenko, P. Guo, Y. I. Chi, RNA 2013, 19, 1226. [134] Y. Zhang, M. Leonard, Y. Shu, Y. Yang, D. Shu, P. Guo, X. Zhang, ACS Nano 2017, 11, 335. [135] J. Cui, K. Germer, T. Wu, J. Wang, J. Luo, S. C. Wang, Q. Wang, X. Zhang, Cancer Res. 2012, 72, 5625. [136] S. L. Daubendiek, K. Ryan, E. T. Kool, J. Am. Chem. Soc. 1995, 117, 7818. [137] S. L. Daubendiek, E. T. Kool, Nat. Biotechnol. 1997, 15, 273. [138] M. G. Mohsen, E. T. Kool, Acc. Chem. Res. 2016, 49, 2540. [139] Y. H. Roh, J. Z. Deng, E. C. Dreaden, J. H. Park, D. S. Yun,\nK. E. Shopsowitz, P. T. Hammond, Angew. Chem., Int. Ed. 2016, 55, 3347. [140] J. B. Lee, J. Hong, D. K. Bonner, Z. Poon, P. T. Hammond, Nat. Mater. 2012, 11, 316. [141] M. Jang, J. H. Kim, H. Y. Nam, I. C. Kwon, H. J. Ahn, Nat. Commun. 2015, 6, 7930. [142] H. Kim, J. Jeong, D. Kim, G. Kwak, S. H. Kim, J. B. Lee, Adv. Sci. 2017, 4, 1600523. [143] H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, Nature 2000, 408, 740. [144] T. Sparwasser, E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, H. Wagner, Eur. J. Immunol. 1998, 28, 2045. [145] A. M. Krieg, A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, D. M. Klinman, Nature 1995, 374, 546. [146] J. Vollmer, A. M. Krieg, Adv. Drug Delivery Rev. 2009, 61, 195. [147] G. Hartmann, G. J. Weiner, A. M. Krieg, Proc. Natl. Acad. Sci. USA 1999, 96, 9305. [148] M. E. Barry, D. Pinto-Gonzalez, F. M. Orson, G. J. McKenzie, G. R. Petry, M. A. Barry, Hum. Gene Ther. 1999, 10, 2461. [149] M. Nishikawa, Y. Mizuno, K. Mohri, N. Matsuoka, S. Rattanakiat,\nY. Takahashi, H. Funabashi, D. Luo, Y. Takakura, Biomaterials 2011, 32, 488.\n1900172 (16 of 16)\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.small-journal.com\n[150] Y. Sanada, T. Shiomi, T. Okobira, M. Tan, M. Nishikawa, I. Akiba, Y. Takakura, K. Sakurai, Langmuir 2016, 32, 3760. [151] N. Matsuoka, M. Nishikawa, K. Mohri, S. Rattanakiat, Y. Takakura, J. Controlled Release 2010, 148, 311. [152] S. Rattanakiat, M. H. Nishikawa, Biomaterials 2009, 30, 5701. [153] Y. Qu, J. Yang, P. Zhan, S. Liu, K. Zhang, Q. Jiang, C. Li, B. Ding,\nACS Appl. Mater. Interfaces 2017, 9, 20324. [154] K. Mohri, M. Nishikawa, N. Takahashi, T. Shiomi, N. Matsuoka,\nK. Ogawa, M. Endo, K. Hidaka, H. Sugiyama, Y. Takahashi, ACS Nano 2012, 6, 5931.\n[155] J. Li, H. Pei, B. Zhu, L. Liang, M. Wei, Y. He, N. Chen, D. Li, Q. Huang, C. Fan, ACS Nano 2011, 5, 8783. [156] V. J. Schüller, S. Heidegger, N. Sandholzer, P. C. Nickels, N. A. Suhartha, S. Endres, C. Bourquin, T. Liedl, ACS Nano 2011, 5, 9696. [157] C. Wang, W. Sun, G. Wright, A. Z. Wang, Z. Gu, Adv. Mater. 2016, 28, 8912. [158] Z. G. Wang, C. Song, B. Ding, Small 2013, 9, 2210. [159] H. J. Kim, A. Kim, K. Miyata, K. Kataoka, Adv. Drug Delivery Rev.\n2016, 104, 61.\nSmall 2019, 1900172"
    } ],
    "references" : [ {
      "title" : "Acc",
      "author" : [ "D. Yang", "M.R. Hartman", "T.L. Derrien", "S. Hamada", "D. An", "K.G. Yancey", "R. Cheng", "M. Ma", "D. Luo" ],
      "venue" : "Chem. Res. 2014, 47",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 1902
    }, {
      "title" : "Immunotherapy based on DNA nanostructures. a) DNA tetrahedron appending CpG ODNs inducing intense immunostimulation",
      "author" : [ "P.A. Guerette", "S. Hoon", "Y. Seow", "M. Raida", "A. Masic", "F.T. Wong", "V.H.B. Ho", "K.W. Kong", "M.C. Demirel", "A. Pena-Francesch", "Nat" ],
      "venue" : "Biotechnol",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2013
    }, {
      "title" : "Chem",
      "author" : [ "K.R. Kim", "D.R. Kim", "T. Lee", "J.Y. Yhee", "B.S. Kim", "I.C. Kwon", "D.R. Ahn" ],
      "venue" : "Commun. 2013, 49",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Bio Mater",
      "author" : [ "C. Yao", "Y. Yuan", "D. Yang", "ACS Appl" ],
      "venue" : "2018, 1",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Eur",
      "author" : [ "T. Sparwasser", "E.S. Koch", "R.M. Vabulas", "K. Heeg", "G.B. Lipford", "J.W. Ellwart", "H. Wagner" ],
      "venue" : "J. Immunol. 1998, 28",
      "citeRegEx" : "144",
      "shortCiteRegEx" : null,
      "year" : 2045
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "With the fast advance of nanotechnology, nucleic acids have been widely explored as generic materials and attracted considerable attention in recent decades.[1] In 1982, Seeman proposed Nucleic acid–based functional nanomaterials (NAFN) have been widely used",
      "startOffset" : 157,
      "endOffset" : 160
    }, {
      "referenceID" : 2,
      "context" : "[93] Ahn and coworkers employed the DNA tetrahedron as an antitumor drug delivery platform to overcome drug resistance in cancer cells (Figure 3a).[70] The DNA tetrahedron loaded DOX efficiently (26 DOX molecules per tetrahedron) by the inherent DNA-intercalation property of DOX.",
      "startOffset" : 147,
      "endOffset" : 151
    }, {
      "referenceID" : 2,
      "context" : "Adapted with permission.[70] Copyright 2013, The Royal Society of Chemistry.",
      "startOffset" : 24,
      "endOffset" : 28
    }, {
      "referenceID" : 3,
      "context" : "Adapted with permission.[105] Copyright 2018, American Chemical Society.",
      "startOffset" : 24,
      "endOffset" : 29
    }, {
      "referenceID" : 3,
      "context" : "release of DOX (Figure 5c).[105] M-DNA nanogels were consisted of magnetic Fe3O4 nanoparticles as the core and crosslinked ssDNA produced via RCA as the shell.",
      "startOffset" : 27,
      "endOffset" : 32
    }, {
      "referenceID" : 4,
      "context" : "[143] Subsequently, stimulated by CpG, the innate immune system produces cytokines[144] (e.",
      "startOffset" : 82,
      "endOffset" : 87
    } ],
    "year" : 2019,
    "abstractText" : "Y. Yuan, Dr. C. Yao, Prof. D. Yang Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE) School of Chemical Engineering and Technology Tianjin University Tianjin 300350, P. R. China E-mail: dayong.yang@tju.edu.cn Dr. Z. Gu School of Chemical Engineering and Australian Centre for NanoMedicine University of New South Wales Sydney, NSW 2052, Australia Prof. D. Luo Department of Biological and Environmental Engineering Cornell University Ithaca, NY 14853, USA E-mail: dl79@cornell.edu Prof. D. Luo CAS Key Laboratory of Nano-Bio Interface Suzhou Institute of Nano-Tech and Nano-Bionics Chinese Academy of Sciences Suzhou 215123, P. R. China The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/smll.201900172.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}